Pacibekitug safely reduces inflammatory biomarkers in kidney disease patients

https://www.news-medical.net/news/20260829/Pacibekitug-safely-reduces-inflammatory-biomarkers-in-kidney-disease-patients.aspx The interleukin-6 (IL-6) antibody, pacibekitug, produced sustained reductions in inflammatory biomarkers in patients with chronic kidney disease at high inflammatory risk, according to results from the phase II TRANQUILITY trial presented in a Hot Line session today at ESC Congress 2026.